Maximus (NYSE:MMS – Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 7.900-8.200 for the period, compared to the consensus earnings per share estimate of 8.430. The company issued revenue guidance of $5.2 billion-$5.4 billion, compared to the consensus revenue estimate of $5.3 billion.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on the stock. Weiss Ratings downgraded shares of Maximus from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 20th. Wall Street Zen raised Maximus from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. Finally, Zacks Research downgraded Maximus from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Two analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Maximus has a consensus rating of “Hold”.
Get Our Latest Stock Analysis on Maximus
Maximus Stock Performance
Maximus (NYSE:MMS – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The health services provider reported $2.22 EPS for the quarter, beating the consensus estimate of $2.21 by $0.01. Maximus had a net margin of 7.02% and a return on equity of 25.10%. Maximus has set its FY 2026 guidance at 7.900-8.200 EPS. As a group, research analysts predict that Maximus will post 8.43 EPS for the current fiscal year.
Maximus Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Friday, August 14th will be issued a dividend of $0.33 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $1.32 dividend on an annualized basis and a dividend yield of 2.1%. Maximus’s payout ratio is 19.76%.
Institutional Investors Weigh In On Maximus
Several hedge funds and other institutional investors have recently made changes to their positions in MMS. Parkside Financial Bank & Trust grew its holdings in shares of Maximus by 13.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,268 shares of the health services provider’s stock worth $109,000 after acquiring an additional 150 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Maximus by 0.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,476 shares of the health services provider’s stock valued at $2,351,000 after purchasing an additional 221 shares during the period. Larson Financial Group LLC boosted its position in shares of Maximus by 13.8% during the third quarter. Larson Financial Group LLC now owns 1,869 shares of the health services provider’s stock valued at $171,000 after purchasing an additional 227 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in shares of Maximus by 225.2% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 439 shares of the health services provider’s stock valued at $38,000 after purchasing an additional 304 shares in the last quarter. Finally, National Bank of Canada FI grew its stake in Maximus by 38.9% in the third quarter. National Bank of Canada FI now owns 1,118 shares of the health services provider’s stock worth $102,000 after purchasing an additional 313 shares during the period. 97.21% of the stock is owned by institutional investors.
About Maximus
Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.
Featured Stories
- Five stocks we like better than Maximus
- Why Analysts Are Bullish on a Stock That’s Down 20%
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.
